Girish Venkataraman to Neoplasm, Residual
This is a "connection" page, showing publications Girish Venkataraman has written about Neoplasm, Residual.
Connection Strength
0.194
-
Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication. Blood Cancer J. 2021 02 18; 11(2):39.
Score: 0.171
-
Bone marrow with gelatinous transformation associated with residual disease in imatinib mesylate-treated chronic myelogenous leukaemia (CML). Pathology. 2012 Jan; 44(1):59.
Score: 0.023